How deadly is Prostate cancer?

['ነዚ ገጽ ስምዓዮ']

መንሽሮ ፕሮስቴት ክሳዕ ክንደይ ቀታሊ እዩ፧

መንሽሮ ፕሮስቴት ኣብ ዓለም ኣብ ደቂ ተባዕትዮ ብብዝሒ ካብ ዝረኣዩ መንሽሮታት ካልኣይ ደረጃ ሒዙ ይርከብ፡ ኣብ 2018 1,276 ሚልዮን ሓደሽቲ ጉዳያት ከም ዝተመዝገበን እዚ ድማ 7.1% ናይ ኩሎም መንሽሮታት ደቂ ተባዕትዮ ከም ዝሽፍን ይግለጽ።

መጠን ሞት ናይ ፕሮስቴት ካንሰር እውን ልዑል እዩ፡ ኣብ 2018 ኣብ መላእ ዓለም 37,005 ሞት ከም ዘጋጠመ ይግመት።

ይኹን እምበር መጠን ሞት ካብ ዞባ ናብ ዞባ ይፈላለ እዩ፣ ምዕራብ ኣፍሪቃ ኣብ ዓለም ሓሙሻይ ደረጃ ዝሓዘት ዝለዓለ ሓደጋ ሞት መንሽሮ ፕሮስቴት ዘለዋ እንትትከውን ናይጀሪያ ድማ ኣብ'ዚ ዞባ ዝዓበየ ቁፅሪ ህዝብን ኢኮኖሚን ዘለዋ ሃገር እያ።

ኣብ ናይጀሪያ መንሽሮ ፕሮስቴት ኣብ ደቂ ተባዕትዮ እቲ ኣዝዩ ልሙድን ቀታሊን መንሽሮ ኮይኑ ኣብ 100,000 ደቂ ተባዕትዮ 32.8 ሕሙማትን 16.3 ሞትን ከምዘስዕብ ይግመት።

እዚ ድማ ካብ ኣብ ሰሜን ኣሜሪካ ዘሎ መጠን ሞት ብዕጽፊ ይዛይድ።

እቲ ሕማም ደንጉዩ ምርኣዩ፣ ንመርመራን ምርካብን ዝወሃብ ውሱን ሃፍቲ፣ ከምኡ እውን ናይቶም ግዳያት ምምዝጋብን ምፅብፃብን ምጉዳሉ ኣብ ናይጄሪያ ልዑል መጠን ሞት ንኽህሉ ኣስተዋፅኦ ኣለዎ።

ኣብ ሕቡራት መንግስታት ኣሜሪካ መንሽሮ ፕሮስቴት ካልኣይ ቀንዲ ጠንቂ ሞት መንሽሮ ደቂ ተባዕትዮ ኮይኑ በብዓመቱ ኣስታት 40,0000 ደቂ ተባዕትዮ በዚ ሕማም ይሞቱ።

ካብ መጀመርያ 1990ታት ጀሚሩ መጠን ሞት መንሽሮ ፕሮስቴት ቀስ ኢሉ እናነከየ እዩ መጺኡ፣ እንተኾነ ግን ዓቢ ናይ ጥዕና ስግኣት ኮይኑ ይርከብ።

ብሓፈሻ ካንሰር ፕሮስቴት ብፍላይ ኣብተን ሕክምናዊ ክንክንን ናይ ምርመራን ዓቕሚ ዘይብለን ዞባታት ቀታሊ ሕማም እዩ።

እንተኾነ፡ ኣቐዲምካ ምልላይን ሕክምናን ውጽኢቱ ብዝበለጸ ከመሓይሽን መጠን ሞት ከጉድልን ይኽእል እዩ።

['መወከሲ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

['ናይ ተሓታትነት መግለጺ: ሕክምናዊ']

['እዚ ወብ ሳይት ንትምህርትን ሓበሬታን ጥራይ እዩ ተዋሂቡ: ሕክምናዊ ምኽሪ ወይ ሞያዊ ኣገልግሎት ንምሃብ ተባሂሉ እተዳለወ ድማ ኣይኰነን።']

['እቲ ሓበሬታ ንዝኾነ ናይ ጥዕና ጸገም ወይ ሕማም ንምፍላጥ ወይ ንምሕካም ክውዕል የብሉን፣ እቶም ውልቃዊ ናይ ሕክምና ምኽሪ ዝደልዩ ድማ ምስ ፍቓድ ዘለዎ ሓኪም ክማኸሩ ኣለዎም።']

['እቲ መልሲ ናይቶም ሕቶታት ዝህብ ኔቭራል ኔት፡ ብፍላይ ኣብ ቁጽሪ ዝተሞርኮሰ ሓበሬታ፡ ንኣብነት፡ ብዝሒ ናይቶም ዝተለኽፉ ሰባት ምስ ዝኸውን፡ ኣዝዩ ዘይቅኑዕ ምዃኑ ኣስተብህል።']

['ኩሉ ግዜ ብዛዕባ ናይ ጥዕና ኩነታትካ ምኽሪ ናይ ሓኪምካ ወይ ካልእ ብቑዕ ናይ ጥዕና ኣገልጋሊ ድለ። ኣብዚ መርበብ ሓበሬታ ዘንበብካዮ ነገር ምኽንያት ናይ ሞያ ናይ ሕክምና ምኽሪ ዕሽሽ ኣይትበል። ናይ ሕክምና ህጹጽ ኩነታት ከጋጥመካ ይኽእል እዩ ኢልካ እንተሓሲብካ 911 ደውል ወይ ናብ ዝቐረበ ህጹጽ ክፍሊ ህጹጽ ረድኤት ብቅልጡፍ ኪድ። እዚ መርበብ ሓበሬታ ወይ ኣጠቓቕምኡ ናይ ሓኪምን ሕሙምን ርክብ ኣይፈጥርን። BioMedLib ወይ ሰራሕተኛታቱ ወይ ዝኾነ ኣበርካቲ ናይዚ መርበብ ሓበሬታ እዚ ኣብዚ ዝተዋህበ ሓበሬታ ወይ ኣጠቓቕምኡ ብዝምልከት ዝኾነ ይኹን መግለጺ ወይ ውክልና ኣይህብን እዩ።']

['ናይ መሰል ተሓታትነት']

['ናይ 1998 ዲጂታል ሚሊኒየም ሕጊ መሰል ደራሲ 17 U.S.C. § 512 (the DMCA) ኣብ ኢንተርኔት ዝረአ ዘሎ ትሕዝቶ ብመሰረት ሕጊ መሰል ደራሲ ኣሜሪካ መሰሎም ዝጥሕስ እዩ ኢሎም ንዝኣምኑ ወነንቲ መሰል ደራሲ ይምልከት። ']

['ዝኾነ ትሕዝቶ ወይ ማተርያል ምስ ዌብሳይትና ወይ ኣገልግሎትና ብምትሕሓዝ ዝተዳለወ ንናይ መሰል ዋንነትካ ዝጥሕስ እዩ ኢልካ ብጽቡቕ እምነት እንተኣሚንካ፣ ንስኻ (ወይ ወኪልካ) ነቲ ትሕዝቶ ወይ ማተርያል ክውገድ ወይ ድማ ናብኡ ምእታው ክኽልከል ዝሓትት ምልክታ ክትልእኸልና ትኽእል ኢኻ።']

['እቲ ምልክታ ብጽሑፍ ብኢሜይል ክለኣኽ ኣለዎ (ናይ ኢሜይል ኣድራሻ ንምርካብ ኣብ "Contact" ዝብል ክፋል ተመልከት) ።']

['እቲ DMCA እዚ ዝስዕብ ሓበሬታታት ክካተት ይሓትት፡ (1) መግለጺ ናይቲ ግህሰት ተፈጻምነት ኣለዎ ተባሂሉ ዝሕመ፡ (2) መግለጺ ናይቲ ግህሰት ተፈጻምነት ኣለዎ ተባሂሉ ዝሕመ ትሕዝቶን ነቲ ትሕዝቶ ክንረኽቦ ዘኽእለና እኹል ሓበሬታን (3) ናይ ርክብ ሓበሬታ፡ እንተላይ ኣድራሻኻ፡ ቁጽሪ ተሌፎንካን ናይ ኢመይል ኣድራሻኻን (4) እቲ ትሕዝቶ በቲ ጥርዓን ዝቐርበሉ መገዲ በቲ በዓል መሰል፡ ወይ ወኪሉ ወይ ብዝኾነ ሕጊ ከምዘይፍቀድ ጽቡቕ እምነት ከም ዘሎካ ዝገልጽ መግለጺ፡']

['(5) እቲ ኣብ ምልክታ ዘሎ ሓበሬታ ልክዕ ምዃኑን ነቲ ዝተጣሕሰ መሰል ናይ ምጥባቕ ስልጣን ከምዘለካን ብገበን ናይ ሓሶት ምስክርነት ዝተፈረመ መግለጺኻ፣']

["ከምኡ'ውን (6) ናይ ዋና መሰል ደራሲ ወይ ብስም ዋና መሰል ደራሲ ክሰርሕ ዝተፈቕደሉ ሰብ፡ ኣካላዊ ወይ ኤለክትሮኒካዊ ፊርማ። "]

['እዚ ኩሉ ኣብ ላዕሊ ዝተጠቕሰ ሓበሬታ ዘይምምላእ ነቲ ጥርዓንካ ናይ ምምላስ መስርሕ ክድንጉዮ ይኽእል እዩ።']

['ርክብ']

['ዝኾነ ሕቶ / ሓሳብ ምስ ዝህልወኩም ብኢሜይል ስደዱልና።']

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ብዛዕባ']

['BioMedLib ሕቶን መልስን ንምፍጣር ኣውቶማቲክ ኮምፒዩተራት (ማሽን-ሊንጊንግ ኣልጎሪዝም) ይጥቀም።']

["ካብ 35 ሚልዮን ናይ ባዮሜዲካል ጽሑፋት ናይ PubMed/Medline ጀሚርና፡ ከምኡ'ውን ናይ RefinedWeb ዌብሳይታት።"]

['ኣብ "References" ከምኡውን "Disclaimer" ተመልከት።']